Comparing biweekly single-dose actinomycin D with multiday methotrexate therapy for low-risk gestational trophoblastic neoplasia (FIGO Score 0–4): study protocol for a prospective, multicentre, randomized trial

Comparing biweekly single-dose actinomycin D with multiday methotrexate therapy for low-risk gestational trophoblastic neoplasia (FIGO Score 0–4): study protocol for a prospective, multicentre, randomized trial

Abstract Background Single-agent chemotherapy using methotrexate or actinomycin D is the first-line treatment for patients with low-risk gestational trophoblastic neoplasia. Various methotrexate-based and actinomycin D-based single-agent regimens can be used. However, there is insufficient evidence...

Full description

Bibliographic Details
Main Authors: Fang Jiang, Ming-yi Mao, Yang Xiang, Xin Lu, Chong-li Guan, Lan-zhou Jiao, Xi-Run Wan, Feng-Zhi Feng, Tong Ren, Jun-Jun Yang, Jun Zhao
Format: Article
Language:English
Published: BMC 2023-08-01
Series:BMC Cancer
Subjects:
Gestational trophoblastic neoplasia
Actinomycin D
Methotrexate
Low risk
Online Access:https://doi.org/10.1186/s12885-023-11225-2

Internet

https://doi.org/10.1186/s12885-023-11225-2

Similar Items